Japan’s biggest pharma co., Takeda, teams with Melbourne’s BioCurate to expedite new drug development
29 Nov 2019
Victorian medicines accelerator, BioCurate, is partnering with Takeda
Pharmaceutical Company Limited to expedite the development of new
therapeutics and drugs.
Founded in June 2016 by Monash University and the University of Melbourne
with support from the Victorian Government, BioCurate is an independent
‘venture catalyst’ for potential new treatments. It focuses on early-phase
drug development, where new concepts often fail due to lack of resources.
BioCurate aims to be a global leader in the translation of basic medical
research into therapeutic treatments. Its two founding universities have
wide-ranging medical research expertise. In combination, they rank within
the top five academic institutions globally for pharmacology, immunology
and metabolism medicine, according to BioCurate.
The bio-accelerator’s new partner, Takeda, is the largest pharmaceuticals
company in Asia, with approximately 50,000 employees. The company
specialises in oncology, gastro disorders and neurology.
Takeda’s Global Head of Research, Steven Hitchcock, says his company will
bring expertise in clinical development and commercialisation to the
‘Together, we will help identify and nurture the discoveries from
BioCurate’s ecosystem that have the greatest potential to become
transformational new therapies for patients in need,’ he says.
BioCurate Chief Executive Officer, Dr C. Glenn Bagley, welcomed the tie-up
‘BioCurate is very pleased to expand our collaborative linkages with
experts who are able to provide invaluable scientific advice, commercial
insight and partnering opportunities,’ he says.
Through its Center for External Innovation, Takeda has more than 200 active
partnerships around the world. Takeda’s partnerships in Australia include
both academia and companies. Its COCKPI-T® open innovation funding platform
was introduced in Australia in 2018.